Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 1Waldenstrom Macroglobulinemia 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Estrogen Receptor and/or Progesterone Receptor Positive 1Ependymoma 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

X-Rays 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Specimen Handling 4Nuclear Medicine Department, Hospital 4Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2Vemurafenib 2LY3023414 2sonidegib 1sodium thiosulfate 1ensartinib 1cixutumumab 1cabozantinib 1Restraint, Physical 1Pharmacogenomic Variants 1MLN 8237 1Cyproheptadine 1Arsenic Trioxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hepatoblastoma × Pharmacogenomic Variants × Clear all
NCT03698994 2026-05-27

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 9 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡